BAIAP2L1

Across TCGA pan-cancer cohorts, BAIAP2L1 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated BAIAP2L1 data layer compared with 26 for mass-spec protein and 6 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BAIAP2L1 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated BAIAP2L1 expression acts as an unfavorable survival marker.

HNSC, LUAD, and BLCA are the cancer types where BAIAP2L1 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	III,IV	0.050	0.611	<.001	42	view →
LUAD	OS	Median	All	0.291	0.837	<.001	31	view →
BLCA	DFS	Median	III,IV	0.094	0.489	.005	9	view →
LIHC	OS	Median	All	0.144	0.688	.013	9	view →
SARC	OS	Median	All	0.238	0.826	.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
ESCA	DFS	Median	II,III,IV	0.186	0.525	.019	6	view →
STAD	DFS	Median	All	0.231	0.632	.047	3	view →
SKCM	OS	Median	All	0.333	0.780	.046	3	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

BAIAP2L1–HNSC (DFS)

Open the HNSC breakdown →